Puma Biotechnology | PBYI - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Agios Pharmaceuticals USD 1.06B 44.38M 2026-09
Alnylam Pharmaceuticals USD -84.37M 166.42M 2026-09
Amgen USD 653M 94.99B 2026-09
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 55.63M 7.67M 2026-09
Daiichi Sankyo JPY 14.13B 10.56B 2026-09
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 269M 22M 2026-09
Glaxosmithkline GBP 264.74M 72.01M 2026-09
Incyte USD 605K 23K 2026-09
MacroGenics USD 4.4M 493K 2026-06
Moderna USD 10.96B 527M 2026-06
Novartis USD 468M 6M 2026-09
Pfizer USD 662M 5M 2026-09
PTC Therapeutics USD 3.21B 42.76M 2026-09
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
Takeda JPY 63.38B 466M 2026-09
TG Therapeutics USD 16.57M 8.91M 2026-06
Ultragenyx Pharmaceutical USD 20M 2M 2026-09
Vanda Pharmaceuticals -1.37B 1.97B 2025-12
Vertex Pharmaceuticals USD 36M 32.7M 2026-09